Using AI to Detect Heart Failure
Every fifty-six seconds, someone dies from cardiovascular disease. Chronic-lung disease, meanwhile, is the world's third-leading cause of death.
As with many illnesses, the key to saving lives is to identify it and take action early. That’s what Vironix was designed to do.
This medical-technology company makes Artificial Intelligence-enabled therapeutic monitoring software. This helps doctors catch and intervene early on dangerous health episodes.
Vironix’s patent-pending software outperforms the current standard of care in detecting/triaging heart failure, COPD, and asthma flareups. The company completed the 2021 Mass Challenge Accelerator and has Letters of Intent that represent a $150 million annual revenue opportunity.
Just enter your e-mail address below & get this guide instantly
No thanks, I’d like to continue making next to nothing in the stock market.
